Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Takei

Showing results (61-70 of 172) with videos related to

Pageof 18
Sort By:
Breast Cancer (Tokyo, Japan)|February 9, 2021
Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancerTomohiro Ochi, Hiroko Tsunoda, Naoko Matsuda, et al.
Surgery Today|February 24, 2006
99mTc-phytate is better than 99mTc-human serum albumin as a radioactive tracer for sentinel lymph node biopsy in breast cancerHiroyuki Takei, Kimito Suemasu, Masafumi Kurosumi, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|February 12, 2014
Enhanced infrared LSPR sensitivity of cap-shaped gold nanoparticles coupled to a metallic filmHiroyuki Takei, Noriyuki Bessho, Aira Ishii, et al.
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi|November 30, 2020
Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast CancerYuji Hayashi, Hiroyuki Takei, Tsuyoshi Saito, et al.
In Vivo (Athens, Greece)|October 30, 2025
Effectiveness of Scalp-cooling Therapy for Preventing Chemotherapy-induced Alopecia in Patients With Breast Cancer: A Prospective Observational Study Focusing on Scalp, Eyebrow, and Eyelash Hair LossTakaaki Fujii, Kei Ichiba, Mayu Aoki, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 26, 2003
A mechanism of drug resistance to tamoxifen in breast cancerJennifer MacGregor Schafer, David J Bentrem, Hiroyuki Takei, et al.
Cancer Research|June 3, 2005
Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancerYuri Yamaguchi, Hiroyuki Takei, Kimito Suemasu, et al.
Experimental and Therapeutic Medicine|September 15, 2012
Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancerKaori Sakuma, Masafumi Kurosumi, Hanako Oba, et al.
Pathology International|October 17, 2006
Immunohistochemical study of the relationship between Ki-67 labeling index of proliferating cells of gynecomastia, histological phase and duration of diseaseSeishi Kono, Masafumi Kurosumi, Hanako Simooka, et al.
BMC Cancer|September 9, 2015
ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumabSasagu Kurozumi, Kenichi Inoue, Hiroyuki Takei, et al.
Pageof 18

Showing results (61-70 of 172) with videos related to

Sort By:
Pageof 18
Breast Cancer (Tokyo, Japan)|February 9, 2021
Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancerTomohiro Ochi, Hiroko Tsunoda, Naoko Matsuda, et al.
Surgery Today|February 24, 2006
99mTc-phytate is better than 99mTc-human serum albumin as a radioactive tracer for sentinel lymph node biopsy in breast cancerHiroyuki Takei, Kimito Suemasu, Masafumi Kurosumi, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|February 12, 2014
Enhanced infrared LSPR sensitivity of cap-shaped gold nanoparticles coupled to a metallic filmHiroyuki Takei, Noriyuki Bessho, Aira Ishii, et al.
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi|November 30, 2020
Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast CancerYuji Hayashi, Hiroyuki Takei, Tsuyoshi Saito, et al.
In Vivo (Athens, Greece)|October 30, 2025
Effectiveness of Scalp-cooling Therapy for Preventing Chemotherapy-induced Alopecia in Patients With Breast Cancer: A Prospective Observational Study Focusing on Scalp, Eyebrow, and Eyelash Hair LossTakaaki Fujii, Kei Ichiba, Mayu Aoki, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 26, 2003
A mechanism of drug resistance to tamoxifen in breast cancerJennifer MacGregor Schafer, David J Bentrem, Hiroyuki Takei, et al.
Cancer Research|June 3, 2005
Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancerYuri Yamaguchi, Hiroyuki Takei, Kimito Suemasu, et al.
Experimental and Therapeutic Medicine|September 15, 2012
Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancerKaori Sakuma, Masafumi Kurosumi, Hanako Oba, et al.
Pathology International|October 17, 2006
Immunohistochemical study of the relationship between Ki-67 labeling index of proliferating cells of gynecomastia, histological phase and duration of diseaseSeishi Kono, Masafumi Kurosumi, Hanako Simooka, et al.
BMC Cancer|September 9, 2015
ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumabSasagu Kurozumi, Kenichi Inoue, Hiroyuki Takei, et al.
Pageof 18